Daily Roundup

IMC.ASX RDX.ASX JLG.ASX PME.ASX JHX.ASX

Immuron Submits IMM-529 IND to FDA

Immuron Limited has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for the clinical development of IMM-529. This new IND proposes the development of IMM-529 for the treatment of Clostridioides difficile (C. diff) infection (CDI) and prevention of recurrent CDI (rCDI). The company plans to initiate a Phase 2 clinical trial for IMM-529 in individuals with CDI during the first half of 2026.

Redox 2025 AGM Presentation and Chair Address

Redox Ltd (ASX:RDX) held its 2025 Annual General Meeting, where the Chair and CEO provided an overview of the company's strong performance in FY25. Despite macroeconomic headwinds, Redox increased sales revenue by 9.4% and gross profit by 1%, with a conversion margin of 45.3%. The Board is committed to Environmental, Social, and Governance (ESG) initiatives and maintains a simplistic approach to executive remuneration. Redox is well-positioned for future growth, with a robust balance sheet and clear strategy.

Scheme Meetings - Chair's address and presentation

Johns LYNG Group Limited (JLG) has convened Scheme Meetings for shareholders to consider and vote on a proposed acquisition by Sherwood BidCo Pty Ltd. The Scheme Consideration of $4.00 cash per share represents a premium of 77% to JLG's closing price. The Independent Expert has concluded that the Scheme is fair and reasonable and in the best interests of JLG shareholders.

Johns LYNG Group Ltd Announces Scheme Approval

Johns LYNG Group Limited (JLG) has announced that shareholders have voted in favor of the proposed scheme of arrangement, under which Sherwood BidCo Pty Ltd will acquire 100% of the company's shares. The scheme remains subject to court approval and other conditions precedent.

Pro Medicus signs A$10M deal with University Heidelberg

Pro Medicus Limited, a leading healthcare informatics company, has signed a 5-year, A$10M Enterprise PACS deal with University Hospital Heidelberg (UKHD) and German Cancer Research Institute (DKFZ). The Visage 7 Enterprise Imaging Platform will enable UKHD and DKFZ to consolidate their disparate legacy systems, streamline workflows, and provide clinicians with advanced diagnostic tools.

James Hardie Reports Preliminary Q2 Results, Improved Siding & Trim Outlook

James Hardie Industries plc announced preliminary expected financial results for the fiscal second quarter. The company's Siding & Trim sales performance exceeded expectations, with a low single-digit organic net sales decline. AZEK, the company's recent acquisition, also performed well, posting mid-single digit growth in both net sales and sell-through for Deck, Rail & Accessories. James Hardie sees an improved outlook for Siding & Trim and is on track with synergy capture and shelf space expansion initiatives.